Dr Reddy’s Laboratories introduces PamorelinÒ LA - cancer drug

08 Dec 2012 Evaluate

Dr Reddy’s Laboratories, has introduced PamorelinÒ LA in India under an exclusive marketing and sales agreement with Debiopharm Group, Switzerland. The company will import this drug in bulk from Debio Recherche Pharmaceutique and made available primarily to urologists and oncologists across India. PamorelinÒ LA is used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs. 

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×